Free tool
FAERS Monitor: Zolinza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021991 or its brand name (Zolinza, Vorinostat). Reports on generic versions are filed under their own applications.
Reports
2,165
Serious
1,872
86% of reports
Hospitalization
998
Death reported
423
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia239
- thrombocytopenia153
- anaemia135
- product use in unapproved indication133
- diarrhoea130
- nausea128
- fatigue126
- off label use115
- vomiting113
- sepsis111
- platelet count decreased106
- dehydration102
- neutropenia95
- death94
- pyrexia90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 3 |
| 2007 | 43 |
| 2008 | 52 |
| 2009 | 54 |
| 2010 | 82 |
| 2011 | 56 |
| 2012 | 190 |
| 2013 | 263 |
| 2014 | 284 |
| 2015 | 291 |
| 2016 | 106 |
| 2017 | 91 |
| 2018 | 96 |
| 2019 | 46 |
| 2020 | 110 |
| 2021 | 88 |
| 2022 | 141 |
| 2023 | 54 |
| 2024 | 50 |
| 2025 | 36 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,994 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 239 | 35.1 | 31.2 | 7,886 |
| thrombocytopeniaSignal | 153 | 13.3 | 11.4 | 1,736 |
| sepsisSignal | 111 | 9.7 | 8.1 | 859 |
| platelet count decreasedSignal | 106 | 9.7 | 8.0 | 819 |
| dehydrationSignal | 102 | 7.4 | 6.2 | 565 |
| anaemiaSignal | 135 | 6.9 | 5.8 | 678 |
| neutropeniaSignal | 95 | 6.8 | 5.6 | 466 |
| product use in unapproved indicationSignal | 133 | 5.2 | 4.4 | 454 |
| pyrexiaSignal | 90 | 2.5 | 2.1 | 83 |
| vomitingSignal | 113 | 2.3 | 2.0 | 87 |
| diarrhoea | 130 | 2.0 | 1.7 | 62 |
| fatigue | 126 | 1.6 | 1.3 | 27 |
| nausea | 128 | 1.6 | 1.3 | 27 |
| off label use | 115 | 1.3 | 1.1 | 7 |
| death | 94 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.